Episode #17 Christopher Haig, President at Efemoral Medical

About this Video

• Video Title: Episode #17 Christopher Haig, President at Efemoral Medical
• Channel: steve maxson
• Speakers: Steve Maxson, Christopher Haig
• Duration: 00:24:25

Introduction

This video features an interview with Christopher Haig, President of Ephemeral Medical, discussing the challenges in the peripheral artery disease (PAD) space and the company's bioresorbable vascular scaffold system designed to address these challenges. The conversation also touches upon the company's clinical trials, funding, and device development process.

Key Takeaways

1. Challenges in PAD Treatment: Current treatments for PAD, including stents and balloons, have high failure rates and poor long-term outcomes due to the complexity of leg movement and the advanced stage of disease at presentation.
2. Ephemeral Medical's Solution: The company is developing a bioresorbable vascular scaffold system specifically designed for peripheral arteries. This system uses multiple independent, interconnected, balloon-expandable scaffolds for superior radial strength and deliverability, addressing limitations of existing nitinol stents.
3. Scaffold Design and Material: The scaffold is made of PLLA co-polymer for improved ductility and faster bioresorbability (1-2 years) compared to 100% PLA. The co-polymer also reduces the risk of fracture during implantation. A sorimus coating provides anti-proliferation properties.
4. Clinical Trials and Funding: Ephemeral Medical is conducting a first-in-human trial (Ephemeral One) in New Zealand and Australia, with 33 patients enrolled. Initial results will be presented at the Chairing Cost conference in London on April 23rd. The company has secured over $12 million in funding, and is currently raising a Series B round of $20 million to support further development and clinical trials.